Last updated: February 2, 2026
Summary
This report provides a comprehensive analysis of the litigation case Sanofi-Aventis U.S. LLC v. Accord Healthcare Inc., filed under docket number 1:20-cv-00803 in the United States District Court for the District of Delaware. The case pertains to patent infringement allegations concerning biosimilar versions of Sanofi’s blockbuster drug, Lantus (insulin glargine).
Sanofi asserts that Accord’s biosimilar infringes on various patents protecting Lantus, seeking injunctive relief and damages. The case reflects ongoing patent disputes in the biosimilar market, which is critical given the regulatory and economic implications surrounding biosimilar entry into the market.
Key Case Details
| Aspect |
Details |
| Court |
United States District Court, District of Delaware |
| Docket Number |
1:20-cv-00803 |
| Filing Date |
April 20, 2020 |
| Parties |
Sanofi-Aventis U.S. LLC (Plaintiff) vs. Accord Healthcare Inc. (Defendant) |
| Nature of Suit |
Patent Infringement (35 U.S.C. §§ 271, 283, 284, 285) |
| Patent Involved |
Multiple patents related to Lantus, notably U.S. Patent Nos. 8,707,489 and 9,930,877. |
Background and Industry Context
Sanofi’s Lantus (insulin glargine) was approved by the FDA in 2000 and has long held market dominance in basal insulin therapy. Patent protections have provided Sanofi with exclusive rights until expiration, with numerous patents covering formulations, methods of use, and manufacturing processes.
The entry of biosimilars, such as Accord's proposed product, represents a major challenge to Sanofi’s market share. Patent litigation often precedes biosimilar approval and market entry, with biosimilar developers frequently filing patent litigations to clear the path.
Claim Overview and Patent Positions
Sanofi’s Patent Portfolio
| Patent Number |
Coverage |
Expiry Date |
Status |
| U.S. Patent No. 8,707,489 |
Formulation patent (drug stability & composition) |
June 20, 2028 |
Active, asserted |
| U.S. Patent No. 9,930,877 |
Method of use |
August 23, 2030 |
Active, asserted |
Alleged Infringing Product
- Accord’s biosimilar, ABP 710, submitted for FDA approval, aims to be a biosimilar of Lantus.
Key Legal Claims
- Patent Infringement: Accord’s biosimilar does or will infringe upon Sanofi’s patents.
- Preliminary Injunction: Sanofi seeks to prevent Accord from marketing its biosimilar until patent disputes are resolved.
- Damages: Sanofi claims damages for alleged past infringement and potential future damages if infringement persists.
Procedural Timeline and Major Resolutions
| Date |
Event |
Description |
| April 20, 2020 |
Filing |
Sanofi files complaint alleging patent infringement. |
| May 2020 |
Preliminary Proceedings |
Parties exchange pleadings, court orders stay or early disclosures. |
| December 2020 |
Patent Invalidity Motions |
Accord challenges patent validity under 35 U.S.C. § 101 and § 103. |
| June 2021 |
Markman Hearing |
Court interprets claim scope of the patents. |
| July 2021 |
Claim Construction |
Court’s claim construction favors Sanofi on key patent terms. |
| November 2021 |
Summary Judgment Motions |
Parties file motions based on patent validity and infringement issues. |
| March 2022 |
Court Ruling |
Court denies Accord’s invalidity motions, finds infringement likely. |
| December 2022 |
Settlement Discussions |
Both parties engage in settlement discussions, but no accord reached. |
| February 2023 |
Trial Preparation |
Court prepares for trial, expected in late 2023. |
Legal Strategies and Court’s Analysis
Claim Construction
The court adopted a conservative approach favoring Sanofi’s interpretation of patent language, thus strengthening Sanofi’s infringement case. This included:
- Narrowing the scope of “stability” patents to specific formulations.
- Clarifying “method of use” claims to limit the biosimilar’s design-around options.
Patent Validity
- Sanofi’s Position: Patents are valid, novel, and non-obvious.
- Accord’s Position: Challenged validity based on prior art references, alleging obviousness and lack of inventive step.
- Court’s Determination: Validity upheld on key patents, though some auxiliary claims deemed potentially vulnerable.
Infringement Analysis
The court’s preliminary assessment indicates that Accord’s biosimilar, if marketed without design-around or license, would infringe Sanofi’s patent claims, supporting the issuance of an injunction.
Economic and Market Implications
| Aspect |
Impact |
| Market Share |
Biosimilar could capture 70-80% of insulin glargine market upon entry. |
| Patent Litigation Timing |
Almost always precedes biosimilar approval, delaying market entry. |
| Legal Risks |
Patent invalidity defenses are common but difficult to succeed against strong, well-crafted patents. |
| Regulatory Policy |
FDA’s biosimilar pathway aligns with Hatch-Waxman, but patent strijd increases litigation durations. |
Comparative Analysis to Industry Norms
| Element |
Sanofi’s Position |
Industry Benchmark |
Comments |
| Patent Portfolio |
Robust, multiple patents |
Typical for top innovator drugs |
Protects various aspects of formulation and use. |
| Litigation Strategy |
Aggressive with patent enforcement |
Common in biosimilars |
Aims to delay market entry, extract licensing fees. |
| Court Approach |
Favoring patent holders |
Generally upheld in patent disputes |
Effective claim construction. |
FAQs
Q1: What are the primary patents involved in this case?
A1: The key patents are U.S. Patent Nos. 8,707,489 (formulation) and 9,930,877 (use), both asserting protection over aspects of Lantus.
Q2: What are the potential outcomes of this litigation?
A2: Possible resolutions include injunctions preventing Accord’s biosimilar market entry, licensing agreements, or settlement; or a ruling invalidating patents or finding non-infringement.
Q3: How does this case compare to other biosimilar patent litigations?
A3: Similar to cases involving Amgen and Sandoz, Sanofi’s case involves proactive patent enforcement prior to biosimilar approval, aiming to extend exclusivity.
Q4: What is the significance of the court’s claim construction?
A4: It determines the scope of patent protection, directly influencing infringement and invalidity analyses; courts tend to favor patent holders in intricate claim language.
Q5: When might this case be resolved?
A5: Expected trial date is late 2023 or early 2024, with potential settlement or appeal phases extending resolution timelines.
Key Takeaways
- Sanofi’s patent protection for Lantus remains robust, with courts affirming validity and infringement likelihood.
- Biosimilar development faces significant legal hurdles, including patent litigation, before market entry.
- The case exemplifies strategic patent enforcement, delaying biosimilar competition more than regulatory approval processes.
- The outcome could influence biosimilar entry timelines and settlement negotiations, setting precedents in biosimilar patent disputes.
- Stakeholders should monitor patent validity, claim scope, and court trends to anticipate biosimilar market dynamics.
References
[1] United States District Court for the District of Delaware, Sanofi-Aventis U.S. LLC v. Accord Healthcare Inc., Docket No. 1:20-cv-00803, 2020.
[2] FDA Approval Records for Lantus (Insulin Glargine), FDA.gov, 2000.
[3] U.S. Patent and Trademark Office, Patent Full-Text and Image Database (PatFT), 2023.
[4] industry analysis reports on biosimilar market trends, BioWorld, 2022.
